Meeting
2014 ASCO Annual Meeting
Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma.
Authors
Abdullah Khalaf Altwairgi
Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia
Abdullah Khalaf Altwairgi , Waleed Ali Alghareeb , Fouad H AlNajjar , Mohammed Mubasher , Hussain Alhussain , Rasha Mustafa Saleh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02029573
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS2102)
DOI
10.1200/jco.2014.32.15_suppl.tps2102
Abstract #
TPS2102
Poster Bd #
66B
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly dignosed adult glioblastoma patients.
First Author: Martin Kelly Nicholas
Poster
2011 ASCO Annual Meeting
CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
First Author: V. Verschaeve
Poster
2011 ASCO Annual Meeting
Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
First Author: A. M. P. Omuro
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen